Blood pressure control in the patient with difficult-to-control hypertension: Which agent for which patient?

Preventive Cardiology

Volumn 11, Issue 1, 2008, Pages 42-49

  Bakris, George L ^a   Sowers, James R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; LISINOPRIL; METOLAZONE; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RESISTANT HYPERTENSION; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; CLINICAL TRIAL; DIET;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS AS TOPIC; DIET; DIURETICS; HUMANS; HYPERTENSION;

EID: 41149119424     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1520-037X.2007.08148.x     Document Type: Article

References (16)

1. Winkleby MA, Kraemer HC, Ahn DK, et al. Ethnic and socioeconomic differences in cardiovascular disease risk factors: Findings for women from the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA. 1998; 280(4): 356-362.
2. Sheps SG, Black HR, Cohen JD, et al, for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program; 1997.
3. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6): 1206-1252.
4. Berenson GS, Voors AW, Webber LS, et al. Racial differences of parameters associated with BP levels in children-the Bogalusa heart study. Metabolism. 1979; 28(12): 1218-1228.
5. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293(13): 1595-1608.
6. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA. 2002; 288(19):2421-2431.
7. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al, on behalf of INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003; 290(21): 2805-2816.
8. Lindholm LH, Ibsen H, Dahlof B, et al; for LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002; 359(9311): 1004-1010.
9. Sacks FM, Svetkey LP, Vollmer WM, et al, on behalf of the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001; 344(1): 3-10.
10. Douglas JG, Bakris GL, Epstein M, et al, on behalf of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163(5): 525-541.
11. Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press. 2007; 16(2): 80-86.
12. Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006; 29(12): 2592-2597.
13. Carter BL, Sica DA. Strategies to improve the cardiovascular risk profile of thiazide-type diuretics as used in the management of hypertension. Expert Opin Drug Saf. 2007; 6(5): 583-594.
14. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006; 47(3): 352-358.
15. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med. 2006; 355(4): 385-392.
16. Sarafidis P, Bakris GL. State of hypertension management in the United States: Confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). In press.